XTL Biopharmaceuticals Ltd. (XTLB.TA)
ILA 4.8
(4.35%)
ILA 4.8
(4.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 765 Thousand | 880 Thousand | 1.03 Million | 948 Thousand | 842 Thousand | 793 Thousand |
| Selling, General and Administrative Expenses | 734 Thousand | 850 Thousand | 1 Million | 910 Thousand | 807 Thousand | 755 Thousand |
| Research and Development Expenses | 31 Thousand | 30 Thousand | 30 Thousand | 38 Thousand | 35 Thousand | 38 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 765 Thousand | 880 Thousand | 1.03 Million | 948 Thousand | 842 Thousand | 793 Thousand |
| Operating Income | -765 Thousand | -880 Thousand | -1.03 Million | -948 Thousand | -842 Thousand | -793 Thousand |
| Interest Expense | - | - | - | - | 29 Thousand | - |
| Income Tax Expense | - | 468 Thousand | -1.46 Million | -166 Thousand | -69 Thousand | -80 Thousand |
| Earnings before Tax | -1.78 Million | -1.34 Million | 435 Thousand | -782 Thousand | -1.34 Million | 2.98 Million |
| Net Income | -1782.00 | -1.34 Million | 435 Thousand | -782 Thousand | -1.34 Million | 2.98 Million |
| Earnings Per Share Basic | - | -0.00 | 0.00 | -0.00 | -0.00 | 0.01 |
| Earnings Per Share Diluted | - | -0.00 | 0.00 | -0.00 | -0.00 | 0.01 |
| Weighted Average Shares Outstanding | 544.95 Million | 544.9 Million | 615.54 Million | 514.2 Million | 514.2 Million | 514.2 Million |
| Weighted Average Shares Outstanding (Diluted) | 544.9 Million | 544.9 Million | 615.54 Million | 514.2 Million | 514.2 Million | 514.2 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -764 Thousand | -879 Thousand | -1.03 Million | -947 Thousand | - | -792 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 175 Thousand | 333.00 | 1746.00 | 151 Thousand | 163 Thousand | 251 Thousand |
| Selling, General and Administrative Expenses | 169 Thousand | 194.00 | - | 145 Thousand | 157 Thousand | 238 Thousand |
| Research and Development Expenses | 6000.00 | 6.00 | - | 6000.00 | 6000.00 | 13 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 175 Thousand | 333.00 | 1746.00 | 151 Thousand | 163 Thousand | 251 Thousand |
| Operating Income | -175 Thousand | -200.00 | -765.00 | -151 Thousand | -163 Thousand | -251 Thousand |
| Interest Expense | 16 Thousand | - | - | 28 Thousand | 32 Thousand | 25 Thousand |
| Income Tax Expense | 6000.00 | -43.81 Thousand | -167.89 Thousand | 19 Thousand | 23 Thousand | 13 Thousand |
| Earnings before Tax | 485 Thousand | -284.00 | -1782.00 | -215 Thousand | -364 Thousand | -919 Thousand |
| Net Income | 485 Thousand | -284.00 | -1782.00 | -215 Thousand | -364 Thousand | -919 Thousand |
| Earnings Per Share Basic | 0.00 | - | - | -0.00 | -0.00 | -0.00 |
| Earnings Per Share Diluted | 0.00 | - | - | -0.00 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 544.9 Million | 544.9 Million | 544.95 Million | 544.9 Million | 544.9 Million | 544.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 544.94 Million | 544.9 Million | 544.9 Million | 544.9 Million | 544.9 Million | 544.9 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -165 Thousand | -199.75 | - | -142 Thousand | -154 Thousand | -239 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
INV
KMK
0165
DRXGY
AMSU
DIS